Navigation Links
2011 ASH Annual Meeting to highlight latest hematology research, clinical care breakthroughs
Date:12/1/2011

WASHINGTON The American Society of Hematology (ASH) will host more than 20,000 attendees from around the globe at its 53rd annual meeting December 10-13 at the San Diego Convention Center in San Diego, CA. The ASH annual meeting, the premier medical meeting for physicians and researchers in the field, will showcase the latest research and clinical advances in hematology.

"2011 has proven to be an inspiring and rewarding year for hematology, filled with new discoveries that are bringing us one step closer to conquering blood diseases," said ASH President J. Evan Sadler, MD, PhD, of the Washington University School of Medicine in St. Louis. "I hope that these scientific presentations, coupled with the diverse offering of educational and professional development opportunities at the Society's 53rd Annual Meeting, will leave attendees inspired to use their new knowledge to further advance the field in 2012."

Data from more than 4,200 scientific abstracts representing more than 1,000 oral and 3,000 poster presentations will reveal the latest research in the field during the meeting. These include six of the top-scoring abstracts to be highlighted during the Plenary Scientific Session and six Late-Breaking Abstracts representing studies with novel data of high impact.

Exciting new offerings for the 2011 ASH Annual Meeting include a Special Symposium on quality of care, "Quality Indicators: Examples and Relevance to Hematology," which will focus on clinical areas of hematology for which quality indicators have been developed and are available. This new symposium will examine how such quality measures are derived and measured, and the importance of adhering to these standards.

The 2011 meeting also marks the debut of the ASH annual meeting mobile application for iPhone, Android, and Blackberry smartphones, as well as iPad and Android tablet devices. This exclusive app, available now in iTunes and the Android Market, and coming soon to Blackberry AppWorld, will feature full text of all annual meeting abstracts, articles from Hematology 2011 (The Education Program Book), maps, exhibitor listings, and other general meeting information.

Other 2011 ASH Annual Meeting highlights include special symposia, the Education Program, the Scientific Program, and a host of lectures and seminars. The Education Program will offer nearly 30 sessions on important areas of clinical progress, including advances in genomic studies of hematologic malignancies and new management strategies for bone failure syndromes, as well as two sessions held jointly with the American Association of Blood Banks (AABB) on transfusion medicine. The Scientific Program will feature 17 sessions on the hottest areas of hematology research, including discussions of metabolic and DNA methylation changes in leukemia and innovative strategies to enhance regenerative potential of hematopoietic stem cells.

Several renowned hematologists will present this year's Special Lectures. Peter Carmeliet, MD, PhD, will examine the fundamentals and medical relevance of angiogenesis during the 2011 Ham-Wasserman Lecture, "Angiogenesis in Health and Disease," on Saturday, December 10. On Monday, December 12, George Q. Daley, MD, PhD, will present the E. Donnall Thomas Lecture, "Hematopoietic, Embryonic, and Induced Pluripotent Stem Cells: Diseases, Myths, and Medicines," which will explore the possibilities and obstacles surrounding the use of genetically modified human embryonic stem cells and personalized induced pluripotent cells derived from patients by somatic cell reprogramming. Also on Monday, December 12, Ernest Beutler Lecture and Prize recipients Janet D. Rowley, MD, and Brian J. Druker, MD, will highlight their achievements in chronic myeloid leukemia research and treatment during their lecture, "Chronic Myeloid Leukemia (CML): A Success Story from Chromosomes to Effective Therapy." The Presidential Symposium on Tuesday, December 13, will focus on recent advances in understanding bone marrow failure syndromes, featuring Monica Bessler, MD, PhD, Benjamin Ebert, MD, DPhil, and Alan D'Andrea, MD.

The Society will honor several hematologists with individual awards for their achievements during the 2011 meeting. On Sunday, December 11, ASH will honor David Nathan, MD, with the Society's highest award, the Wallace H. Coulter Award for Lifetime Achievement in Hematology, for his important discoveries in thalassemia and other blood disorders, his tireless promotion of translational research, and his dedication to training several generations of leaders in the field. ASH will also recognize Nancy C. Andrews, MD, PhD, and Malcolm K. Brenner, MD, PhD, with Mentor Awards on Sunday for their sustained commitment to the training and career development of junior hematologists. On Tuesday, December 13, ASH will present Christoph Klein, MD, PhD, with the Dameshek Prize for his outstanding accomplishments, which have had a large impact on the understanding of human blood and the immune system. Also on Tuesday, Ching-Hon Pui, MD, will receive the Henry M. Stratton Medal for his many significant contributions to childhood leukemia research.


'/>"/>
Contact: Lindsey Love
llove@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. The American Society of Hematology announces awards honoring abstracts at 2011 Annual Meeting
2. Kessler Foundation announces 24th Annual Physical Medicine & Rehabilitation Board Review Course
3. NYU Langone experts present at annual meeting of Radiological Society of North America
4. 19 Million New STD Infections Reported Annually, CDC Says
5. NYU Langone experts present at Society for Neuroscience Annual Meeting
6. Society for Integrative Oncology releases findings presented at annual meeting
7. ACAAI Annual Meeting abstracts: Improved outcomes for adults with allergies and asthma
8. High rate of false-positives with annual mammogram
9. Annual cost of violence pegged at $6.9 billion after women leave abusive partners, UBC research
10. 6th Annual International Translational Medicine Symposium held at Penn
11. Media advisory: 2011 AAPS Annual Meeting and Exposition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: